Profile data is unavailable for this security.
About the company
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
- Revenue in USD (TTM)0.00
- Net income in USD-210.50m
- Incorporated2020
- Employees100.00
- LocationMoonLake ImmunotherapeuticsDorfstrasse 29ZUG 6300SwitzerlandCHE
- Phone+41 415108022
- Websitehttps://moonlaketx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Iovance Biotherapeutics Inc | 250.43m | -397.63m | 936.84m | 838.00 | -- | 1.30 | -- | 3.74 | -1.20 | -1.20 | 0.7552 | 1.82 | 0.2642 | 4.22 | 4.09 | 298,836.50 | -41.94 | -50.14 | -48.13 | -56.84 | 23.96 | -- | -158.78 | -1,097.64 | 3.00 | -- | 0.0014 | -- | 13,698.99 | -- | 16.18 | -- | 9.86 | -- |
| CareDx Inc | 358.00m | 60.76m | 943.79m | 644.00 | 22.78 | 3.03 | 12.54 | 2.64 | 0.8055 | 0.8055 | 6.15 | 6.05 | 0.7874 | 4.87 | 6.25 | 555,897.50 | 13.37 | -11.64 | 16.67 | -13.85 | 67.62 | 66.00 | 16.97 | -18.51 | 2.75 | -- | 0.00 | -- | 19.07 | 21.31 | 127.62 | -- | 14.13 | -- |
| Sana Biotechnology Inc | 0.00 | -234.41m | 945.60m | 194.00 | -- | 4.77 | -- | -- | -0.9708 | -0.9708 | 0.00 | 0.7447 | 0.00 | -- | -- | 0.00 | -47.13 | -39.42 | -51.39 | -43.39 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.82 | -- | 5.06 | -- |
| ARS Pharmaceuticals Inc | 142.77m | -80.04m | 955.87m | 162.00 | -- | 6.47 | -- | 6.70 | -0.9012 | -0.9012 | 1.38 | 1.49 | 0.4836 | 3.56 | 7.67 | 921,109.70 | -27.11 | -14.27 | -30.61 | -14.82 | 89.40 | -- | -56.06 | -224.85 | 6.51 | -- | 0.3946 | -- | 297,063.30 | -- | 114.71 | -- | 42.45 | -- |
| Vir Biotechnology Inc | 16.86m | -499.65m | 962.75m | 408.00 | -- | 1.21 | -- | 57.10 | -3.62 | -3.62 | 0.1223 | 5.73 | 0.0134 | -- | -- | 41,323.53 | -39.69 | -4.58 | -42.97 | -5.34 | 95.94 | -- | -2,963.54 | -13.27 | -- | -- | 0.00 | -- | -13.90 | 55.77 | 15.14 | -- | -3.97 | -- |
| ORIC Pharmaceuticals Inc | 0.00 | -135.27m | 970.00m | 106.00 | -- | 2.38 | -- | -- | -1.73 | -1.73 | 0.00 | 4.18 | 0.00 | -- | -- | 0.00 | -36.90 | -36.70 | -39.10 | -38.98 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.96 | -- | 9.12 | -- |
| Ventyx Biosciences Inc | 0.00 | -106.61m | 1.00bn | 83.00 | -- | 5.20 | -- | -- | -1.50 | -1.50 | 0.00 | 2.68 | 0.00 | -- | -- | 0.00 | -41.60 | -50.81 | -43.60 | -53.75 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 29.97 | -- | -- | -- |
| Savara Inc | 0.00 | -115.65m | 1.05bn | 59.00 | -- | 9.45 | -- | -- | -0.535 | -0.535 | 0.00 | 0.5461 | 0.00 | -- | -- | 0.00 | -60.91 | -36.72 | -66.05 | -39.40 | -- | -- | -- | -109,477.80 | -- | -- | 0.2399 | -- | -- | -- | -75.29 | -- | -29.93 | -- |
| Capricor Therapeutics Inc | 11.13m | -81.99m | 1.05bn | 160.00 | -- | 12.55 | -- | 94.60 | -1.80 | -1.80 | 0.2451 | 1.83 | 0.1015 | -- | 47.48 | 69,565.69 | -74.74 | -45.52 | -96.03 | -61.91 | -- | -- | -736.62 | -248.15 | -- | -- | 0.0387 | -- | -11.55 | 85.83 | -81.57 | -- | -- | -- |
| MoonLake Immunotherapeutics | 0.00 | -210.50m | 1.05bn | 100.00 | -- | 3.26 | -- | -- | -3.33 | -3.33 | 0.00 | 4.54 | 0.00 | -- | -- | 0.00 | -45.83 | -- | -50.02 | -- | -- | -- | -- | -- | -- | -43.63 | 0.2021 | -- | -- | -- | -230.31 | -- | -- | -- |
| Septerna Inc | 22.05m | -58.81m | 1.09bn | 75.00 | -- | 2.81 | -- | 49.64 | -1.51 | -1.51 | 0.5304 | 8.71 | 0.0565 | -- | 4.98 | 293,933.30 | -15.06 | -- | -16.99 | -- | -- | -- | -266.77 | -- | -- | -- | 0.00 | -- | 611.92 | -- | -12,762.79 | -- | -- | -- |
| Compass Therapeutics Inc. | 0.00 | -65.81m | 1.11bn | 35.00 | -- | 5.27 | -- | -- | -0.4577 | -0.4577 | 0.00 | 1.18 | 0.00 | -- | -- | 0.00 | -34.60 | -37.49 | -36.20 | -40.90 | -- | -- | -- | -28,561.77 | -- | -- | 0.00 | -- | -- | -- | -16.19 | -- | -37.62 | -- |
| Zenas Biopharma Inc | 15.00m | -189.90m | 1.13bn | 130.00 | -- | 4.52 | -- | 75.19 | -12.67 | -12.67 | 0.4565 | 4.65 | 0.0414 | -- | -- | 115,384.60 | -52.35 | -- | -60.38 | -- | -- | -- | -1,265.99 | -- | -- | -116.56 | 0.2709 | -- | -90.00 | -- | -322.87 | -- | -- | -- |
Data as of Feb 06 2026. Currency figures normalised to MoonLake Immunotherapeutics's reporting currency: US Dollar USD
48.95%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BVF Partners LPas of 06 Nov 2025 | 19.75m | 27.88% |
| Deep Track Capital LPas of 05 Nov 2025 | 4.61m | 6.51% |
| Avoro Capital Advisor LLCas of 30 Sep 2025 | 2.00m | 2.82% |
| Cormorant Asset Management LPas of 30 Sep 2025 | 1.99m | 2.82% |
| Balyasny Asset Management LPas of 30 Sep 2025 | 1.70m | 2.40% |
| Adage Capital Management LPas of 30 Sep 2025 | 1.50m | 2.12% |
| Schonfeld Strategic Advisors LLCas of 30 Sep 2025 | 965.41k | 1.36% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2025 | 822.96k | 1.16% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 724.74k | 1.02% |
| TIAA-CREF Investment Management LLCas of 30 Sep 2025 | 611.41k | 0.86% |
More ▼
Data from 30 Sep 2025 - 30 Sep 2025Source: FactSet Research Systems Inc.
